CDC25 as a common therapeutic target for triple-negative breast cancer - the challenges ahead

The dual phosphatase CDC25 has recently been identified as a target for diverse triple-negative breast cancers including RB1/PTEN/P53-deficient tumors. Moreover, CDC25 inhibitors effectively synergize with PI3K inhibitors to suppress tumor growth. We discuss these findings and the challenges that li...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Mol Cell Oncol
Главные авторы: Zacksenhaus, Eldad, Liu, Jeff C., Granieri, Letizia, Vorobieva, Ioulia, Wang, Dong-Yu, Ghanbari-Azarnier, Ronak, Li, Huiqin, Ali, Amjad, Chung, Philip E.D., Ju, YoungJun, Jiang, Zhe, Shrestha, Mariusz
Формат: Artigo
Язык:Inglês
Опубликовано: Taylor & Francis 2018
Предметы:
Author's Views
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6149702/
https://ncbi.nlm.nih.gov/pubmed/30250928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23723556.2018.1481814
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы